A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
Status:
Completed
Trial end date:
2013-12-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and efficacy when administering PA21
with calcium carbonate in hemodialysis patients with hyperphosphatemia for 12 weeks.